2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1971

Healthcare Utilization and Direct Medical Costs of Giant Cell Arteritis

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1289

Healthcare Utilization Differences According to Sex Among Children and Adults in Medicaid with Incident Lupus Nephritis

Health Services Research Poster II (ACR): Healthcare Access, Patterns of Medication Use and Workforce Considerations

9:00AM-11:00AM: Abstract Number: 1829

Heart Rate Variability Is Associated with SLE Flare and with TNF- and IFN-Mediated Signaling

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1390

Hidradenitis Suppuritiva Is Associated with Inflammatory Eye Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

9:00AM-11:00AM: Abstract Number: 1627

HIF-1alpha Knockdown Down-Regulates Glycolytic Metabolism and Induces Rheumatoid Synovial Fibroblast Cell Death

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1565

High Disease Activity over Time and Persistent Inflammation Are Associated with Increased Risk of Cardiovascular Disease in Patients with Early Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1693

High Prevalence of Cardiac Disease in Patients with Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1698

High Prevalence of Traditional Cardiovascular Risk Factors in an Ankylosing Spondylitis Cohort

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1119

High Resolution Motif Mapping of in Situ Anti-Native-Vimentin Antibodies in Lupus Tubulointerstitial Nephritis

B cell Biology and Targets in Rheumatolid Arthritis and other Autoimmune Disease Poster

9:00AM-11:00AM: Abstract Number: 1379

High Serum IgG4 Concentration Is a Risk Factor for Relapse in IgG4-Related Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

9:00AM-11:00AM: Abstract Number: 1218

Higher Education Is Associated with a Better Rheumatoid Arthritis Outcome Concerning Pain and Function but Not Disease Activity: Results from Swedish Registers

Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1845

HMGB1 Early Marker in Lupus Nephritis

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1322

How Can We Reduce the Time for Scoring Radiographic Joint Damage in Rheumatoid Arthritis? Initial Results with a New Computer-Based Documentation Tool

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1954

How Can We Use Ultrasound in the Diagnosis and Management of Patients with Giant Cell Arteritis?

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1352

How Frequently Does Tuberculosis Screening Test Become Positive in Rheumatic Patients Treated with ANTI-Tumor Necrosis Factor-ALPHA Therapy? an Analysis of Risk Factors

Infection-related Rheumatic Disease: Poster Session

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].